Search for new therapeutics against HIV-1 via dual inhibition of RNase H and integrase: current status and future challenges

Future Med Chem. 2021 Feb;13(3):269-286. doi: 10.4155/fmc-2020-0257. Epub 2021 Jan 5.

Abstract

Reverse transcriptase and integrase are key enzymes that play a pivotal role in HIV-1 viral maturation and replication. Reverse transcriptase consists of two active sites: RNA-dependent DNA polymerase and RNase H. The catalytic domains of integrase and RNase H share striking similarity, comprising two aspartates and one glutamate residue, also known as the catalytic DDE triad, and a Mg2+ pair. The simultaneous inhibition of reverse transcriptase and integrase can be a rational drug discovery approach for combating the emerging drug resistance problem. In the present review, the dual inhibition of RNase H and integrase is systematically discussed, including rationality of design, journey of development, advancement and future perspective.

Keywords: dual inhibition; integrase; molecular hybridization; resistance; reverse transcriptase.

Publication types

  • Review

MeSH terms

  • Anti-HIV Agents / chemistry*
  • Anti-HIV Agents / metabolism
  • Anti-HIV Agents / therapeutic use
  • Catalytic Domain
  • Drug Design
  • HIV Infections / drug therapy
  • HIV Infections / metabolism
  • HIV Integrase / chemistry
  • HIV Integrase / metabolism*
  • HIV Reverse Transcriptase / antagonists & inhibitors
  • HIV Reverse Transcriptase / metabolism
  • HIV-1 / enzymology*
  • Humans
  • Ribonuclease H / antagonists & inhibitors
  • Ribonuclease H / metabolism*
  • Structure-Activity Relationship

Substances

  • Anti-HIV Agents
  • HIV Integrase
  • HIV Reverse Transcriptase
  • Ribonuclease H